Evaluation of CEM43 degrees CT90 thermal dose in superficial hyperthermia: a retrospective analysis.
OBJECTIVE
Prospective use of the CEM43 degrees CT90 thermal dose parameter has been proposed for hyperthermia treatments. This study evaluates the CEM43 degrees CT90 parameter by means of a retrospective analysis of recurrent breast cancer patients receiving reirradiation plus hyperthermia.


METHODS
CEM43 degrees CT90 was calculated for 72 patients who received 8 x 4 Gy reirradiation plus 8 x 1 h hyperthermia for adenocarcinoma recurrences at the chest wall. Associations of prognostic factors CEM43 degrees CT90 and tumor maximum diameter with endpoints complete response (CR), duration of local control (DLC), and overall survival (OS) were determined.


RESULTS
A highly significant inverse association between CEM43 degrees CT90 and tumor maximum diameter (rho = -0.7, p < 1e-6) was found. The association between CR and CEM43 degrees CT90 was not significant (p > or = 0.7). CEM43 degrees CT90 was associated with DLC. Both CEM43 degrees CT90 and tumor maximum diameter had a significant association with survival (p < or = 0.01). The association with thermal dose, when adjusted for tumor maximum diameter, was not significant for either CR, DLC, or OS (p > 0.2).


CONCLUSIONS
In this retrospective study, no clear CEM43 degrees CT90 thermal dose targets or associations with clinical endpoints could be established.
de Bruijne
Maarten
M
Hyperthermia Unit, Department of Radiation Oncology, Erasmus MC - Daniel den Hoed Cancer Center, Rotterdam, The Netherlands. maarten_de_bruijne@hotmail.com
van der Holt
Bronno
B
van Rhoon
Gerard C
GC
van der Zee
Jacoba
J
D000230:Adenocarcinoma / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D001943:Breast Neoplasms / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D004867:Equipment Design; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced / Q000295:instrumentation*; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D012189:Retrospective Studies; D012881:Skin Temperature; D035441:Thoracic Wall; D047368:Tumor Burden
Strahlenther Onkol. 2009 Feb;185(2):120-6
19240999
Int J Radiat Oncol Biol Phys. 1996 Jul 1;35(4):731-44
8690639
Int J Radiat Oncol Biol Phys. 1989 Mar;16(3):551-8
2646257
Int J Hyperthermia. 1998 Jan-Feb;14(1):13-27
9483443
Int J Radiat Oncol Biol Phys. 1995 Nov 1;33(4):887-99
7591899
Strahlenther Onkol. 2009 Oct;185(10):669-74
19806332
Int J Radiat Oncol Biol Phys. 1993 Jan 15;25(2):289-97
8420877
Int J Hyperthermia. 2008 Mar;24(2):123-40
18283589
J Clin Oncol. 2005 May 1;23(13):3079-85
15860867
Int J Hyperthermia. 2010;26(7):638-48
20849259
Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):365-75
9457823
Int J Hyperthermia. 2003 May-Jun;19(3):267-94
12745972
Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):371-80
9308941
Int J Hyperthermia. 1994 Jul-Aug;10(4):457-83
7963805
Int J Hyperthermia. 2005 Dec;21(8):779-90
16338861
Int J Radiat Oncol Biol Phys. 1984 Jun;10(6):787-800
6547421
Int J Hyperthermia. 2005 Dec;21(8):761-7
16338859
Int J Hyperthermia. 1997 Jul-Aug;13(4):343-64
9278766
Am J Clin Oncol. 1991 Apr;14(2):133-41
1903023
Strahlenther Onkol. 2008 Mar;184(3):163-8
18330513
Int J Hyperthermia. 2008 Mar;24(2):111-22
18283588
Int J Hyperthermia. 1992 Nov-Dec;8(6):719-32
1479198
Br J Cancer. 1999 Feb;79(3-4):483-90
10027317
Strahlenther Onkol. 2008 Jul;184(7):347-53
19016032